60 DEGREES PHARMACEUTICALS, INC.
SXTP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SXTP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SXTP
60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company focused on developing and commercializing treatments for infectious diseases, with a single marketed product and a lead pipeline candidate, tafenoquine, for babesiosis. The company faces significant financial challenges, including a going concern qualification from its auditors, and is dependent on raising additional capital to fund operations.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials · 2 catalysts for 60 DEGREES PHARMACEUTICALS, INC..
60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company focused on developing and commercializing treatments for infectious diseases, with a single marketed product and a lead pipeline candidate, tafenoquine, for babesiosis. The company faces significant financial challenges, including a going concern qualification from its auditors, and is dependent on raising additional capital to fund operations.
- 60 Degrees Pharmaceuticals has a single marketed product and is developing tafenoquine for severe babesiosis [sec_mda · as of 2026-03-30].
- The company reported cash & equivalents of $1.0M, total revenue of $0.2M, and a net loss of -$2.3M as of 2026-06-30 [sec].
- Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring operating losses [sec_mda · as of 2026-05-15].
- The company plans to submit a New Drug Application for tafenoquine to the FDA before the end of Q1 2028, contingent on clinical trial results [news · published 2026-06-03].
- A Phase 2 topline readout for tafenoquine is expected on 2026-10-30 [upcoming catalysts].
What works
- The company has identified a total addressable market for babesiosis treatment of $1.1 billion through patent expiration in 2035 [sec_mda · as of 2025-11-13].
- The company intends to apply for a Commissioner's National Priority Review Voucher, which could expedite regulatory review if the tafenoquine trial is successful [news · published 2026-06-03].
What to weigh
- The company has a going concern qualification from its auditors, indicating substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-15].
- The company has not demonstrated the ability to generate enough revenues to cover operating expenses and expects to need additional capital to fund operations [sec_mda · as of 2026-03-30].
- The company's future is dependent on the outcome of clinical trials and regulatory interactions, which are subject to risks and uncertainties [news · published 2026-07-09].
From the filings
Quoted directly from source documents.
Auditors expressed substantial doubt about the company's ability to continue as a going concern.
“In their audit report for the fiscal year ended December 31, 2025 , our auditors have expressed their concern as to our ability to continue as a going concern.”
SEC MD&A · May 15, 2026
The company plans to submit an NDA for tafenoquine before Q1 2028.
“The Company intends to submit an application for a Commissioner's National Priority Review Voucher if the outcome of any interim and/or final analysis of the Company's randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis supports moving forward with a New Drug Application submission to the U.S. Food and Drug Administration ("FDA") before the end of the first quarter of 2028.”
News · June 3, 2026
The company identified a $1.1 billion total addressable market for babesiosis treatment.
“we announced that we had determined the total addressable market (TAM) for Babesiosis treatment to be $1.1 billion through patent expiration in 2035.”
SEC MD&A · November 13, 2025
The company has recurring operating losses and needs to raise capital.
“Since our inception, we have not demonstrated the ability to generate enough revenues to date to cover operating expenses and”
SEC MD&A · May 15, 2026
Catalyst timeline
- 2026-10-30 · Phase2_Topline · tafenoquine — Phase 2 Readout: tafenoquine — Topline results from the Phase 2 trial of tafenoquine in patients hospitalized with severe babesiosis will be released, determining the path to a potential NDA submission.
- 2035-12-02 · Patent_Expiry · ARAKODA — Patent/Exclusivity Expiry: ARAKODA — The patent or exclusivity for ARAKODA expires, which could open the market to generic competition.
Risks & what to watch (4)›
Key risks
- Going concern risk — Auditors have expressed substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-05-15].
- Dependence on tafenoquine trial — The company's future hinges on the outcome of the tafenoquine Phase 2 trial and subsequent regulatory approval [news · published 2026-06-03].
- Limited cash runway — With only $1.0M in cash as of 2026-06-30, the company may need to raise capital soon to fund operations [sec].
- Single product revenue — The company relies on a single marketed product and has not achieved profitability [sec_mda · as of 2026-03-30].
What to watch
- Phase 2 topline data for tafenoquine in severe babesiosis, expected on 2026-10-30 [upcoming catalysts].
- Company's ability to raise additional capital to fund operations and clinical development [sec_mda · as of 2026-05-15].
- Regulatory interactions regarding the potential NDA submission for tafenoquine, planned before Q1 2028 [news · published 2026-06-03].
- Patent expiry for ARAKODA on 2035-12-02, which could impact market exclusivity [upcoming catalysts].
Sources: News · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run 60 DEGREES PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available 60 DEGREES PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.5 months
D/E 0.67 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~61d
1 buy · 0 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$285K
| Holder | Shares | Value |
|---|---|---|
| kathmere capital management, llc | 144,683 | $253K |
| geode capital management, llc | 16,295 | $29K |
| barclays plc | 1,856 | $3K |
| osaic holdings, inc. | 25 | $43 |
| twin peaks wealth advisors, llc | 8 | $14 |
| citigroup inc | 1 | $2 |
Short Interest
as of May 22, 2026- % of float
- 5.5%
- Days to cover
- 0.6
- Shares short
- 142,704
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SXTP short interestGovernance
Frequently asked questions
What is the AI investment thesis for 60 DEGREES PHARMACEUTICALS, INC.?
60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company focused on developing and commercializing treatments for infectious diseases, with a single marketed product and a lead pipeline candidate, tafenoquine, for babesiosis. The company faces significant financial challenges, including a going concern qualification from its auditors, and is dependent on raising additional capital to fund operations.
What is 60 DEGREES PHARMACEUTICALS, INC.'s next catalyst?
60 DEGREES PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: tafenoquine" — expected October 30, 2026.
Who is the CEO of 60 DEGREES PHARMACEUTICALS, INC.?
Dr. Geoffrey Stuart Dow Ph.D. is the chief executive officer of 60 DEGREES PHARMACEUTICALS, INC. (SXTP).
Where is 60 DEGREES PHARMACEUTICALS, INC. headquartered?
60 DEGREES PHARMACEUTICALS, INC. (SXTP) is headquartered in Washington, DC, United States.
What therapeutic areas does 60 DEGREES PHARMACEUTICALS, INC. focus on?
60 DEGREES PHARMACEUTICALS, INC. develops therapies across Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.